Effect of C1-esterase-inhibitor on capillary leak and inflammatory response syndrome during arterial switch operations in neonates

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 15, Issue 4, 2001, Pages 469-473

  Tassani, Peter ^a,b   Kunkel, Regula ^a,b   Richter, Josef A ^a,b   Oechsler, Hannelore ^a,b   Lorenz, Hans P ^a,b   Braun, Siegmund L ^a,b   Eising, Gregory P ^a,b   Haas, Felix ^a,b   Paek, Sun U ^a,b   Bauernschmitt, Robert ^a,b   Jochum, Marianne ^a,b   Lange, Rüdiger ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

C1 esterase inhibitor; Cardiopulmonary bypass; Complement; Inflammation; Inhibitors

Indexed keywords

ANESTHETIC AGENT; BERINERT; BLOOD CLOTTING FACTOR 12; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1S INHIBITOR; FENTANYL; FLUNITRAZEPAM; INTERLEUKIN 6; PANCURONIUM; PLACEBO; PREKALLIKREIN;

ARTICLE; CARDIOPULMONARY BYPASS; CARDIOVASCULAR SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONGENITAL HEART DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EXTRACORPOREAL OXYGENATION; GREAT VESSELS TRANSPOSITION; HUMAN; INFLAMMATION; NEWBORN; NEWBORN SURGERY; PEDIATRIC ANESTHESIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 17944383154     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/jcan.2001.24989     Document Type: Article

References (44)

1. Transposition of the great arteries and intact ventricular septum: Anatomical repair in the neonate
2. The arterial switch operation: An eight-year experience
3. Experience with anatomical correction of transposition of the great arteries (TGA)
4. Complement and contact activation during cardiovascular operations in infants
5. The systemic inflammatory response to cardiopulmonary bypass: Pathophysiological, therapeutic, and pharmacological considerations
6. Inflammatory reaction and capillary leak syndrome related to cardiopulmonary bypass in neonates undergoing cardiac operations
7. Complement and the damaging effects of cardiopulmonary bypass
8. Complement activation during cardiopulmonary bypass in infants and children: Relation to postoperative multiple system organ failure
9. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass
10. Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass
11. Successful use of C1-esterase-inhibitor protein in a patient with hereditary angioneurotic edema requiring coronary artery bypass surgery
12. Complement activation during bypass in acquired c1-esterase-inhibitor deficiency
13. Cardiopulmonary bypass in hereditary angioedema
14. C1-inhibitor substitution as ultima ratio therapy in septic shock: Experience with 15 patients
15. Rescue therapy with C1-esterase-inhibitor concentrate after emergency coronary surgery for failed PTCA
16. Intracoronary application of C1-esterase-inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion
17. Evaluation of an automated immunoassay method for cytokine measurement using the immulite immunoassay system
18. Studies on synthetic peptide substrates for F XII enzymes
19. A microtitre chromogenic substrate assay for factor XII
20. Description and evaluation of a new chromogenic substrate assay kit for the determination of prekallikrein in human plasma
21. Pooled patient samples as reference material for D-Dimer
22. Possible mechanism for in vitro complement activation in blood and plasma samples: Futhan/EDTA controls in vitro complement activation
23. Complement activation, cytokines, and adhesion molecules in children undergoing cardiac surgery with or without cardiopulmonary bypass
24. Hemofiltration during cardiopulmonary bypass in pediatric cardiac surgery: Effects on hemostasis, cytokines, and complement components
25. Ultrafiltration and modified ultrafiltration in pediatric open heart operations
26. Influence of combined zero-balanced and modified ultrafiltration on the systemic inflammatory response during coronary artery bypass grafting
27. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes: A European multicentre study
28. Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin
29. Heparin-coated cardiopulmonary bypass equipment: II. Mechanisms for reduced complement activation in vivo
30. Inflammatory response to cardiopulmonary bypass using roller or centrifugal pumps
31. Seal-less centrifugal blood pump with magnetically suspended rotor: Rot-a-flot
32. Pulmonary function after biventricular bypass for autologous lung oxygenation
33. Drew-Anderson technique attenuates systemic inflammatory response syndrome and improves respiratory function after coronary artery bypass grafting
34. Does high-dose methylprednisolone in aprotinin-treated patients attenuate the systemic inflammatory response during CABG procedures?
35. High-dose aprotinin modulates the balance between pro- and anti-inflammatory response during CABG
36. Aprotinin in open-heart surgery of infants and children using the heart-lung machine
37. Influence of C1-inhibitor on inflammation, edema and shock
38. Activity of C1-esterase-inhibitor in patients with vascular leak syndrome after bone marrow transplantation
39. C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2
40. Capillary leakage syndrome complicating chemotherapy in an infant with Wilms' tumor
41. Initial studies on the administration of C1-esterase-inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy
42. Angioneurotische Ödeme
43. Ärzteschaft: Schwerwiegende Thrombenbildung nach Berinert HS
44. Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes